Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
54
CRNX Quote, Financials, Valuation and Earnings
Last price:
$47.39
Seasonality move
:
-5.19%
Day range:
$44.52 - $48.13
52-week range:
$24.10 - $60.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2,850.95x
P/B ratio:
4.16x
Volume:
1.2M
Avg. volume:
1.4M
1-year change:
-16.98%
Market cap:
$4.5B
Revenue:
$1M
EPS (TTM):
-$4.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRNX
Crinetics Pharmaceuticals, Inc.
|
$394K | -$1.25 | 21.75% | -53.87% | $80.21 |
|
AMGN
Amgen, Inc.
|
$9B | $5.01 | 4.56% | 309.55% | $324.25 |
|
LLY
Eli Lilly & Co.
|
$16.1B | $5.89 | 30.84% | 53.75% | $1,045.59 |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$247.7M | -$1.99 | 201.43% | -81.62% | $563.80 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
UTHR
United Therapeutics Corp.
|
$812.9M | $7.31 | 11.26% | 17.13% | $518.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRNX
Crinetics Pharmaceuticals, Inc.
|
$46.98 | $80.21 | $4.5B | -- | $0.00 | 0% | 2,850.95x |
|
AMGN
Amgen, Inc.
|
$345.42 | $324.25 | $186B | 26.70x | $2.38 | 2.76% | 5.21x |
|
LLY
Eli Lilly & Co.
|
$1,033.56 | $1,045.59 | $925.1B | 51.12x | $1.50 | 0.58% | 15.86x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$579.89 | $563.80 | $13.2B | -- | $0.00 | 0% | 17.36x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.06 | $0.85 | $133.6M | 1.78x | $0.80 | 0% | 2.06x |
|
UTHR
United Therapeutics Corp.
|
$480.96 | $518.25 | $20.7B | 18.23x | $0.00 | 0% | 7.41x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRNX
Crinetics Pharmaceuticals, Inc.
|
4.38% | 0.825 | 1.25% | 14.74x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.293 | 6.22% | 0.65x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
35.63% | -0.048 | 3.33% | 3.14x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
UTHR
United Therapeutics Corp.
|
-- | 1.213 | -- | 5.61x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRNX
Crinetics Pharmaceuticals, Inc.
|
-$869K | -$142.6M | -35.8% | -37.41% | -99710.49% | -$111.6M |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$268.8M | -$114M | -32.91% | -40.56% | -39.68% | $76M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
UTHR
United Therapeutics Corp.
|
$698.6M | $389.3M | 18.69% | 19.2% | 48.69% | $346.1M |
Crinetics Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns CRNX or AMGN?
Amgen, Inc. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of 33.55%. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital CRNXCrinetics Pharmaceuticals, Inc.-607.69% -$1.38 $1.1B AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About CRNX or AMGN?
Crinetics Pharmaceuticals, Inc. has a consensus price target of $80.21, signalling upside risk potential of 70.74%. On the other hand Amgen, Inc. has an analysts' consensus of $324.25 which suggests that it could fall by -6.13%. Given that Crinetics Pharmaceuticals, Inc. has higher upside potential than Amgen, Inc., analysts believe Crinetics Pharmaceuticals, Inc. is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRNXCrinetics Pharmaceuticals, Inc.11 2 0 AMGNAmgen, Inc.10 15 2 -
Is CRNX or AMGN More Risky?
Crinetics Pharmaceuticals, Inc. has a beta of 0.200, which suggesting that the stock is 79.99% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock CRNX or AMGN?
Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.76% to investors and pays a quarterly dividend of $2.38 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.
-
Which has Better Financial Ratios CRNX or AMGN?
Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Amgen, Inc.'s PE ratio is 26.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,850.95x versus 5.21x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRNXCrinetics Pharmaceuticals, Inc.2,850.95x -- $143K -$130.1M AMGNAmgen, Inc.5.21x 26.70x $9.6B $3.2B
-
Which has Higher Returns CRNX or LLY?
Eli Lilly & Co. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of 31.72%. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital CRNXCrinetics Pharmaceuticals, Inc.-607.69% -$1.38 $1.1B LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About CRNX or LLY?
Crinetics Pharmaceuticals, Inc. has a consensus price target of $80.21, signalling upside risk potential of 70.74%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,045.59 which suggests that it could grow by 1.16%. Given that Crinetics Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Crinetics Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings CRNXCrinetics Pharmaceuticals, Inc.11 2 0 LLYEli Lilly & Co.17 8 0 -
Is CRNX or LLY More Risky?
Crinetics Pharmaceuticals, Inc. has a beta of 0.200, which suggesting that the stock is 79.99% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.
-
Which is a Better Dividend Stock CRNX or LLY?
Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRNX or LLY?
Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 51.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,850.95x versus 15.86x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRNXCrinetics Pharmaceuticals, Inc.2,850.95x -- $143K -$130.1M LLYEli Lilly & Co.15.86x 51.12x $17.6B $5.6B
-
Which has Higher Returns CRNX or MDGL?
Madrigal Pharmaceuticals, Inc. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of -39.75%. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.
Company Gross Margin Earnings Per Share Invested Capital CRNXCrinetics Pharmaceuticals, Inc.-607.69% -$1.38 $1.1B MDGLMadrigal Pharmaceuticals, Inc.93.57% -$5.08 $972.1M -
What do Analysts Say About CRNX or MDGL?
Crinetics Pharmaceuticals, Inc. has a consensus price target of $80.21, signalling upside risk potential of 70.74%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $563.80 which suggests that it could fall by -2.78%. Given that Crinetics Pharmaceuticals, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Crinetics Pharmaceuticals, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRNXCrinetics Pharmaceuticals, Inc.11 2 0 MDGLMadrigal Pharmaceuticals, Inc.13 1 0 -
Is CRNX or MDGL More Risky?
Crinetics Pharmaceuticals, Inc. has a beta of 0.200, which suggesting that the stock is 79.99% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.
-
Which is a Better Dividend Stock CRNX or MDGL?
Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRNX or MDGL?
Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,850.95x versus 17.36x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRNXCrinetics Pharmaceuticals, Inc.2,850.95x -- $143K -$130.1M MDGLMadrigal Pharmaceuticals, Inc.17.36x -- $287.3M -$114.2M
-
Which has Higher Returns CRNX or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of -255.85%. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital CRNXCrinetics Pharmaceuticals, Inc.-607.69% -$1.38 $1.1B NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About CRNX or NBY?
Crinetics Pharmaceuticals, Inc. has a consensus price target of $80.21, signalling upside risk potential of 70.74%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -19.81%. Given that Crinetics Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Crinetics Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRNXCrinetics Pharmaceuticals, Inc.11 2 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is CRNX or NBY More Risky?
Crinetics Pharmaceuticals, Inc. has a beta of 0.200, which suggesting that the stock is 79.99% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock CRNX or NBY?
Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRNX or NBY?
Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,850.95x versus 2.06x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRNXCrinetics Pharmaceuticals, Inc.2,850.95x -- $143K -$130.1M NBYNovaBay Pharmaceuticals, Inc.2.06x 1.78x $521K -$1.3M
-
Which has Higher Returns CRNX or UTHR?
United Therapeutics Corp. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of 42.36%. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat United Therapeutics Corp.'s return on equity of 19.2%.
Company Gross Margin Earnings Per Share Invested Capital CRNXCrinetics Pharmaceuticals, Inc.-607.69% -$1.38 $1.1B UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B -
What do Analysts Say About CRNX or UTHR?
Crinetics Pharmaceuticals, Inc. has a consensus price target of $80.21, signalling upside risk potential of 70.74%. On the other hand United Therapeutics Corp. has an analysts' consensus of $518.25 which suggests that it could grow by 7.75%. Given that Crinetics Pharmaceuticals, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Crinetics Pharmaceuticals, Inc. is more attractive than United Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings CRNXCrinetics Pharmaceuticals, Inc.11 2 0 UTHRUnited Therapeutics Corp.7 5 0 -
Is CRNX or UTHR More Risky?
Crinetics Pharmaceuticals, Inc. has a beta of 0.200, which suggesting that the stock is 79.99% less volatile than S&P 500. In comparison United Therapeutics Corp. has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.874%.
-
Which is a Better Dividend Stock CRNX or UTHR?
Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. United Therapeutics Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRNX or UTHR?
Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are smaller than United Therapeutics Corp. quarterly revenues of $799.5M. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than United Therapeutics Corp.'s net income of $338.7M. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while United Therapeutics Corp.'s PE ratio is 18.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,850.95x versus 7.41x for United Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRNXCrinetics Pharmaceuticals, Inc.2,850.95x -- $143K -$130.1M UTHRUnited Therapeutics Corp.7.41x 18.23x $799.5M $338.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
